Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Uterine Cervical Neoplasms × defactinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 7 Ovarian Neoplasms 4 Mesothelioma, Malignant 4 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 2 Mesothelioma 2 Lung Neoplasms 2 Glioblastoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Phase IB 1 Neoplasms, Mesothelial 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Endometrioid 1 Brain Neoplasms 1 Advanced Colorectal Cancer 1 Adenoma 1 Adenocarcinoma of Lung 1

Interventions

Cisplatin 158 Radiotherapy 72 Brachytherapy 67 Paclitaxel 64 Carboplatin 61 pembrolizumab 57 Bevacizumab 36 Colposcopy 28 Radiation 27 Gemcitabine 27 Topotecan 25 Surveys and Questionnaires 25 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 23 Magnetic Resonance Spectroscopy 21 human papillomavirus vaccine, L1 type 16, 18 19 Papillomavirus Vaccines 19 Nivolumab 19 Platinum 18 Blood Specimen Collection 18 Biopsy 17 Drug Therapy 16 Radiotherapy, Intensity-Modulated 15 Docetaxel 15 Cyclophosphamide 15 1,2-diaminocyclohexaneplatinum II citrate 15 atezolizumab 13 Taxes 13 Papanicolaou Test 13 Methods 13 Human Papillomavirus DNA Tests 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05512208 2025-10-22

DURAFAK

University of Oklahoma

Phase 2 Recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡